TransCode Therapeutics, Inc. (RNAZ)
NasdaqCM: RNAZ
· 即時價格 · USD
1.69
+0.00 (0.00%)
收盤價： Sep 11, 2026, 3:38 PM
1.69
+0.00%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
TransCode Therapeutics, Inc.（RNAZ）股價、分析與資料
0.00% (1D)
| 買價 | 1.16 |
| 市值 | 1.79M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -46.3M |
| 1.17 | |
| -48.28 | |
| n/a | |
| -2.82 | |
| P/B (ttm) | -0.06 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 2.16 |
| 成交量 | 11,441 |
| 20 日平均成交量 | 44,467 |
| 開盤價 | 1.68 |
| 前收盤價 | 1.69 |
| 當日區間 | 1.63 - 1.73 |
| 52 週範圍 | 1.63 - 20.99 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising brea...
完整的公司簡介財報驚奇
TransCode Therapeutics 已於 Apr 15, 2025 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -1286.15 低於預期 -1196.27, 年增 92.68% 成長.
